LQDA Liquidia Technologies Inc.

Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension. The company is also developing LIQ865, which completed Phase Ib clinical trials for the treatment of local post-operative pain. It has strategic collaboration agreements with GlaxoSmithKline plc and Aerie Pharmaecuticals, Inc. Liquidia Technologies, Inc. was incorporated in 2004 and is headquartered in Morrisville, North Carolina.

$2.58
As of 04/09/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  07/26/2018
Outstanding shares:  43,336,277
Average volume:  738,372
Market cap:   $111,807,595
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    53635D202
ISIN:        US53635D2027
Sedol:      BYVJ8J8
Valuation   (See tab for details)
PE ratio:   -6.95
PB ratio:   1.57
PS ratio:   151.17
Return on equity:   -61.44%
Net income %:   -5,905.17%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy